

Global COVID-19 Vaccine Development Tools Market Size study, by Technology (Lab Technologies, PCR & qPCR, Flow Cytometry, Spectrometry, Electron Microscopy, and Next Generation Sequencing), by End-Use (CROs and Pharma & BioPharma Firms), and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G41464507C5FEN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: G41464507C5FEN

Abstracts

Global COVID-19 Vaccine Development Tools Market is valued approximately at USD 7.12 billion in 2023 and is poised to expand at a steady CAGR of 9.00% over the forecast period 2024–2032. As the world continues to adapt to the long-term presence of SARS-CoV-2 and its variants, the vaccine development landscape is undergoing a profound transformation—driven by the need for agility, accuracy, and global coordination. Tools supporting the development of COVID-19 vaccines, ranging from advanced PCR technologies to next-generation sequencing platforms and high-throughput electron microscopy, have become indispensable assets in streamlining discovery pipelines. Their relevance persists even in post-peak pandemic phases, where booster development, variant surveillance, and universal vaccine R&D dominate the scientific agenda.

The momentum in this market is propelled by the integration of AI-assisted modeling with lab automation, enabling researchers to shorten development timelines without compromising safety and efficacy standards. PCR and qPCR platforms remain the backbone of viral quantification, while flow cytometry is gaining prominence for immune profiling in vaccinated populations. Spectrometry and NGS (next-generation sequencing) are being widely deployed to analyze mutations and map viral evolution in real time, a capability that has grown critical as global vaccination strategies pivot toward bivalent and multivalent formulations. Simultaneously, partnerships between

contract research organizations (CROs) and biopharma firms are intensifying, with shared investment in state-of-the-art instrumentation to support preclinical and clinical milestones.

Yet the market faces key bottlenecks. The global disparity in laboratory infrastructure, intellectual property constraints, and high procurement costs of sophisticated tools act as restraining forces, particularly in low- and middle-income nations. Furthermore, the transition from emergency authorization to standard regulatory protocols has introduced new complexities around validation timelines and compliance. Despite these hurdles, ongoing funding by governments and supranational organizations, including CEPI and WHO-led initiatives, continues to fuel innovation. There is a growing trend toward creating decentralized and mobile diagnostic platforms, particularly in response to future outbreaks or regional flare-ups of COVID-19 and related respiratory pathogens.

Tool manufacturers are also focusing on modularity, miniaturization, and interoperability, allowing multi-functional use across both therapeutic and diagnostic workflows. Electron microscopy platforms are evolving with AI-driven image analysis to speed up structural biology applications, critical for understanding virus-antibody interactions. Meanwhile, the growing prominence of mRNA technology has catalyzed demand for transcriptomics tools and lipid nanoparticle formulation monitoring. These technological convergences are also drawing the attention of venture capital firms, which are increasingly backing startups that bring novel analytical approaches into the vaccine research ecosystem.

From a regional standpoint, North America currently commands a substantial share of the market due to strong R&D capabilities, robust healthcare infrastructure, and the presence of major vaccine developers and CROs. Europe, too, is witnessing accelerated growth, particularly in countries like Germany and the UK, where pandemic preparedness has become a governmental priority. The Asia Pacific region is anticipated to register the fastest CAGR over the forecast period, driven by rapid biotechnology growth in India, China, South Korea, and Australia. Latin America and the Middle East & Africa are gradually expanding their footprint with the help of international grants and public-private collaborations aimed at enhancing local vaccine production capabilities and laboratory diagnostics.

Major market player included in this report are:

Thermo Fisher Scientific Inc.

Bio-Rad Laboratories, Inc.

F. Hoffmann-La Roche Ltd

Agilent Technologies, Inc.

Illumina, Inc.

Merck KGaA

PerkinElmer, Inc.

QIAGEN N.V.

BD (Becton, Dickinson and Company)

Bruker Corporation

Oxford Nanopore Technologies

Tecan Group Ltd

GE Healthcare

Danaher Corporation

Sartorius AG

The detailed segments and sub-segment of the market are explained below:

By Technology

Lab Technologies

PCR & qPCR

Flow Cytometry

Spectrometry

Electron Microscopy

Next Generation Sequencing

By End-Use

CROs

Pharma & BioPharma Firms

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Global COVID-19 Vaccine Development Tools Market Size study, by Technology (Lab Technologies, PCR & qPCR, Flow...

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with country-level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Companies Mentioned

Thermo Fisher Scientific Inc.

Bio-Rad Laboratories, Inc.

F. Hoffmann-La Roche Ltd

Agilent Technologies, Inc.

Illumina, Inc.

Merck KGaA

PerkinElmer, Inc.

QIAGEN N.V.

BD (Becton, Dickinson and Company)

Bruker Corporation

Oxford Nanopore Technologies

Tecan Group Ltd

GE Healthcare

Danaher Corporation

Sartorius AG

Contents

CHAPTER 1. GLOBAL COVID-19 VACCINE DEVELOPMENT TOOLS MARKET EXECUTIVE SUMMARY

- 1.1. Global COVID-19 Vaccine Development Tools Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Technology
 - 1.3.2. By End-Use
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL COVID-19 VACCINE DEVELOPMENT TOOLS MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Consumer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL COVID-19 VACCINE DEVELOPMENT TOOLS MARKET

Global COVID-19 Vaccine Development Tools Market Size study, by Technology (Lab Technologies, PCR & qPCR, Flow...

DYNAMICS

3.1. Market Drivers

- 3.1.1. Demand for Rapid Variant Surveillance and Booster Development
- 3.1.2. Integration of AI-Assisted Modeling and Lab Automation
- 3.1.3. Intensified CRO–Biopharma Collaborations

3.2. Market Challenges

- 3.2.1. Disparity in Global Laboratory Infrastructure
- 3.2.2. Intellectual Property Constraints and High Procurement Costs
- 3.2.3. Transition from Emergency Use to Standard Regulatory Protocols

3.3. Market Opportunities

- 3.3.1. Decentralized and Mobile Diagnostic Platforms
- 3.3.2. Modular, Miniaturized, and Interoperable Instrumentation
- 3.3.3. mRNA Technology–Driven Demand for Transcriptomics and Formulation Tools

CHAPTER 4. GLOBAL COVID-19 VACCINE DEVELOPMENT TOOLS MARKET INDUSTRY ANALYSIS

4.1. Porter's 5 Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Forces
- 4.1.7. Porter's 5 Forces Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunities

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL COVID-19 VACCINE DEVELOPMENT TOOLS MARKET SIZE & FORECASTS BY TECHNOLOGY (2022–2032)

5.1. Segment Dashboard

5.2. Market: Lab Technologies; PCR & qPCR; Flow Cytometry; Spectrometry; Electron Microscopy; NGS Revenue Trend Analysis, 2022 & 2032 (USD Billion)

CHAPTER 6. GLOBAL COVID-19 VACCINE DEVELOPMENT TOOLS MARKET SIZE & FORECASTS BY END-USE (2022–2032)

6.1. Segment Dashboard

6.2. Market: CROs vs. Pharma & BioPharma Firms Revenue Trend Analysis, 2022 & 2032 (USD Billion)

CHAPTER 7. GLOBAL COVID-19 VACCINE DEVELOPMENT TOOLS MARKET SIZE & FORECASTS BY REGION (2022–2032)

7.1. North America Market

7.1.1. U.S. Market

7.1.1.1. Technology Breakdown & Forecasts, 2022–2032

7.1.1.2. End-Use Breakdown & Forecasts, 2022–2032

7.1.2. Canada Market

7.2. Europe Market

7.2.1. UK

7.2.2. Germany

7.2.3. France

7.2.4. Spain

7.2.5. Italy

7.2.6. Rest of Europe

7.3. Asia Pacific Market

7.3.1. China

7.3.2. India

7.3.3. Japan

7.3.4. Australia

7.3.5. South Korea

7.3.6. Rest of Asia Pacific

7.4. Latin America Market

7.4.1. Brazil

7.4.2. Mexico

- 7.4.3. Rest of Latin America
- 7.5. Middle East & Africa Market
 - 7.5.1. Saudi Arabia
 - 7.5.2. South Africa
 - 7.5.3. Rest of Middle East & Africa

CHAPTER 8. COMPETITIVE INTELLIGENCE

- 8.1. Key Company SWOT Analysis
 - 8.1.1. Thermo Fisher Scientific Inc.
 - 8.1.2. Bio-Rad Laboratories, Inc.
 - 8.1.3. F. Hoffmann-La Roche Ltd
- 8.2. Top Market Strategies
- 8.3. Company Profiles
 - 8.3.1. Thermo Fisher Scientific Inc.
 - 8.3.1.1. Key Information
 - 8.3.1.2. Overview
 - 8.3.1.3. Financial (Subject to Data Availability)
 - 8.3.1.4. Product Summary
 - 8.3.1.5. Market Strategies
 - 8.3.2. Agilent Technologies, Inc.
 - 8.3.3. Illumina, Inc.
 - 8.3.4. Merck KGaA
 - 8.3.5. PerkinElmer, Inc.
 - 8.3.6. QIAGEN N.V.
 - 8.3.7. BD (Becton, Dickinson and Company)
 - 8.3.8. Bruker Corporation
 - 8.3.9. Oxford Nanopore Technologies

CHAPTER 9. RESEARCH PROCESS

- 9.1. Research Process
 - 9.1.1. Data Mining
 - 9.1.2. Analysis
 - 9.1.3. Market Estimation
 - 9.1.4. Validation
 - 9.1.5. Publishing
- 9.2. Research Attributes

List Of Tables

LIST OF TABLES

TABLE 1. Global COVID-19 Vaccine Development Tools market, report scope
TABLE 2. Estimates & forecasts by Region 2022–2032 (USD Billion)
TABLE 3. Estimates & forecasts by Technology 2022–2032 (USD Billion)
TABLE 4. Estimates & forecasts by End-Use 2022–2032 (USD Billion)
TABLE 5. North America market estimates & forecasts, 2022–2032 (USD Billion)
TABLE 6. U.S. market estimates & forecasts by segment, 2022–2032 (USD Billion)
TABLE 7. Canada market estimates & forecasts by segment, 2022–2032 (USD Billion)
TABLE 8. Europe market estimates & forecasts, 2022–2032 (USD Billion)
TABLE 9. UK market estimates & forecasts by segment, 2022–2032 (USD Billion)
TABLE 10. Germany market estimates & forecasts by segment, 2022–2032 (USD Billion)
TABLE 11. Asia Pacific market estimates & forecasts, 2022–2032 (USD Billion)
TABLE 12. China market estimates & forecasts by segment, 2022–2032 (USD Billion)
TABLE 13. India market estimates & forecasts by segment, 2022–2032 (USD Billion)
TABLE 14. Latin America market estimates & forecasts, 2022–2032 (USD Billion)
TABLE 15. Brazil market estimates & forecasts by segment, 2022–2032 (USD Billion)
TABLE 16. Middle East & Africa market estimates & forecasts, 2022–2032 (USD Billion)
TABLE 17. Saudi Arabia market estimates & forecasts by segment, 2022–2032 (USD Billion)
TABLE 18. South Africa market estimates & forecasts by segment, 2022–2032 (USD Billion)
TABLE 19. Global market competitive landscape analysis, 2023
TABLE 20. Global market, historical vs. forecast comparison 2022–2032 (USD Billion)

List Of Figures

LIST OF FIGURES

- FIG 1. Market research methodology
- FIG 2. Market estimation techniques
- FIG 3. Size estimates & forecast methods
- FIG 4. Key trends 2023
- FIG 5. Growth prospects 2022–2032
- FIG 6. Porter's 5 Forces model
- FIG 7. PESTEL analysis
- FIG 8. Value chain analysis
- FIG 9. Market by Technology, 2022 & 2032 (USD Billion)
- FIG 10. Market by End-Use, 2022 & 2032 (USD Billion)
- FIG 11. Market by Region, 2022 & 2032 (USD Billion)
- FIG 12. North America market, 2022 & 2032 (USD Billion)
- FIG 13. Europe market, 2022 & 2032 (USD Billion)
- FIG 14. Asia Pacific market, 2022 & 2032 (USD Billion)
- FIG 15. Latin America market, 2022 & 2032 (USD Billion)
- FIG 16. Middle East & Africa market, 2022 & 2032 (USD Billion)
- FIG 17. Company market share analysis (2023)
- FIG 18. Challenges and opportunities framework
- FIG 19. Adoption lifecycle curve
- FIG 20. Investor landscape overview

I would like to order

Product name: Global COVID-19 Vaccine Development Tools Market Size study, by Technology (Lab Technologies, PCR & qPCR, Flow Cytometry, Spectrometry, Electron Microscopy, and Next Generation Sequencing), by End-Use (CROs and Pharma & BioPharma Firms), and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G41464507C5FEN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G41464507C5FEN.html>